Market Overview

AstraZeneca, Bristol-Myers Squibb Announce Positive Phase III Dapagliflozin Data

Share:
Related AZN
Here Are All The Big Biotech Mergers In 2016
Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?
A Merck Versus Bristol Showdown (Seeking Alpha)

AstraZeneca
(NYSE: AZN) and Bristol-Myers
Squibb Company (NYSE: BMY) today announced results from a Phase III
study evaluating dapagliflozin in adult patients with type 2 diabetes
who were inadequately controlled on combination treatment with metformin
plus sulfonylurea. Patients treated with dapagliflozin 10 mg as an
add-on therapy to metformin plus sulfonylurea demonstrated significant
improvements in glycosylated hemoglobin levels (HbA1c) and, among key
secondary endpoints, significant reductions in fasting plasma glucose
(FPG) and in body weight compared to placebo at 24 weeks. Significant
improvements were also observed in seated systolic blood pressure (SBP)
at eight weeks in patients treated with dapagliflozin compared to
placebo. The results were presented today at the 49th Annual

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (AZN + BMY)

View Comments and Join the Discussion!